Wilmington, NC, 12 June 2020 – Catalyst Clinical Research, a Wilmington-based award-winning clinical development and global resourcing organization, announced the hiring of Andrew Zupnick, PhD as Vice President of Oncology Drug Development. Dr. Zupnick will be responsible for growing the organization’s full-service oncology solution, and will support study optimization, training and new initiatives across the commercial and operational teams to keep Catalyst at the forefront of industry trends and cutting-edge oncology therapies.
“Being a scientist by training and having only worked in oncology for the past 20 years, I am passionate about finding new therapies to help patients in their battle against cancer,” says Dr. Zupnick.” Given the complexity of the disease and the novel mechanisms of action being pursued today, there is significant demand for an oncology specialty CRO that can align with the culture and support the pace of innovation within the biotech sector. I’d heard a lot of buzz about Catalyst being the next great oncology CRO and am thrilled to become a part of the team. I am most excited to return to a niche focus and become immersed in a culture that focuses on our people and delivering excellence.”
Bringing a broad base of oncology experience to Catalyst, Dr. Zupnick began his professional career at a niche oncology CRO after graduating from MIT with a B.S. in Biology and Columbia University with a Ph.D. in Biological Sciences with focuses in oncology and cell and molecular biology. Prologue Research was founded out of the James Cancer Center at the Ohio State and acquired in 2010 by Novella Clinical where Dr. Zupnick led the growth of the organization’s oncology division into a market-leading oncology specialty CRO. After the acquisition of Novella by Quintiles, Dr. Zupnick spent nearly seven years working within the standalone CRO which was subsequently rebranded to IQVIA Biotech in 2019.
Catalyst’s Global Head of Clinical Development Solutions, Keya Watkins, stated: “Andrew’s specialized experience in oncology makes him an excellent addition to the clinical development team. His fresh perspective and collaborative approach will greatly contribute to the growing momentum of Catalyst across the industry. Andrew will help us continue to make great strides and breakthroughs in our quest to be the preferred innovative oncology CRO.”
Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry. With offices in the US and EU, the company provides global resourcing solutions, functional and full-service managed solutions, the latter with a focus on oncology therapeutics. Catalyst’s service model is built from more than a decade of listening to customers, devising customer-centric solutions and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.
Catalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.